Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.

ABSTRACT: Biological products for treatment of rheumatoid arthritis usually are cost effective for healthcare systems in Europe, but they are huge financial burden due to the high number of patients and the significant budget impact. The expected saving from introduction on the market of biosimilars are significant and are linked to better access and affordability. The aim of this study was to conduct comparative price analysis of biological products for rheumatoid arthritis therapy among seventeen EU countries. The point of view is that of the Bulgarian pricing and reimbursement system and the chosen countries are those from external reference basket for prices comparison at manufacturing level. All authorized biological products by EMA with therapeutic indication rheumatoid arthritis were selected

SUBMITTER: Manova M 

PROVIDER: S-EPMC6158404 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature